HC Wainwright Issues Positive Estimate for XENE Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at HC Wainwright increased their Q2 2025 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Tuesday, May 13th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($1.08) per share for the quarter, up from their prior forecast of ($1.12). HC Wainwright has a "Buy" rating and a $53.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' FY2025 earnings at ($4.48) EPS, Q2 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.38) EPS, FY2027 earnings at ($5.70) EPS, FY2028 earnings at ($5.11) EPS and FY2029 earnings at ($3.61) EPS.

Several other analysts have also issued reports on XENE. Royal Bank of Canada reduced their price objective on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Finally, StockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $54.82.

Xenon Pharmaceuticals Stock Up 0.3%

NASDAQ:XENE traded up $0.09 on Thursday, reaching $31.04. The company's stock had a trading volume of 286,121 shares, compared to its average volume of 511,887. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00. The stock has a 50 day moving average price of $34.01 and a 200 day moving average price of $37.83. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -11.04 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same quarter in the prior year, the company posted ($0.62) earnings per share.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently modified their holdings of XENE. FMR LLC lifted its position in shares of Xenon Pharmaceuticals by 8.8% during the 4th quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after buying an additional 607,606 shares during the last quarter. Driehaus Capital Management LLC lifted its position in Xenon Pharmaceuticals by 1.4% in the first quarter. Driehaus Capital Management LLC now owns 4,584,859 shares of the biopharmaceutical company's stock valued at $153,822,000 after acquiring an additional 64,264 shares during the last quarter. Wellington Management Group LLP lifted its position in Xenon Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 3,789,197 shares of the biopharmaceutical company's stock valued at $127,128,000 after acquiring an additional 11,586 shares during the last quarter. Braidwell LP boosted its stake in Xenon Pharmaceuticals by 7.6% in the fourth quarter. Braidwell LP now owns 2,913,964 shares of the biopharmaceutical company's stock valued at $114,227,000 after acquiring an additional 206,709 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals by 12.3% during the fourth quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company's stock worth $112,425,000 after purchasing an additional 314,363 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.